BCM
AMPH icon

Bayesian Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bayesian Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,400
Closed -$192K – 399
2016
Q4 		$192K Sell
10,400
-5,800
-36% -$113K 0.05% 530
2016
Q3 		$307K Buy
+16,200
New +$294K 0.2% 190

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bayesian Capital Management's AMPH Position: Q1 2017 in Review

Bayesian Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2017, closing a stake of 10,400 shares — an estimated $192K sold.

Bayesian Capital Management first reported a position in AMPH in Q3 2016 and held it in 2 quarters. The position peaked at $307K in Q3 2016. 116 funds tracked by Wall St. Rank hold AMPH as of Q1 2017.

  • Bayesian Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Bayesian Capital Management sold 10,400 Amphastar Pharmaceuticals shares in Q1 2017, an estimated $192K.
  • Bayesian Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Bayesian Capital Management's Amphastar Pharmaceuticals position peaked at $307K in Q3 2016.
  • 116 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2017.

Based on Bayesian Capital Management's 13F filing for Q1 2017, filed 15 May 2017.